Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Annals of Surgical Oncology
Published in: Annals of Surgical Oncology 7/2011

01-07-2011 | Gastrointestinal Oncology

Interleukin-2 −330T>G Genetic Polymorphism Associates with Prognosis Following Surgery for Thoracic Esophageal Squamous Cell Cancer

Authors: Satoru Motoyama, MD, PhD, Masatomo Miura, PhD, Yudai Hinai, Kiyotomi Maruyama, MD, PhD, Shuetsu Usami, MD, PhD, Kei Yoshino, MD, Toshinobu Nakatsu, MD, Hajime Saito, MD, PhD, Yoshihiro Minamiya, MD, PhD, Jun-ichi Ogawa, MD, PhD

Published in: Annals of Surgical Oncology | Issue 7/2011

Login to get access

Abstract

Background

Key molecules in the T helper (Th)1 and Th2 pathways underlie differential responses to the progression and surgical treatment of cancer. We investigated the relationship between Th1/Th2 cytokine polymorphism and prognosis in patients with thoracic esophageal squamous cell cancer.

Materials and Methods

The study participants were 159 Japanese patients treated for thoracic esophageal squamous cell cancer with curative esophagectomy at Akita University Hospital. We determined the associations between prognosis following esophagectomy and genetic polymorphisms in Th1 cytokines (interleukin [IL]-2, Interferon-γ, IL-12β), and Th2 cytokines (IL-4, IL-10).

Results

IL-2 −330T>G genetic polymorphism was significantly associated with prognosis after esophagectomy. Univariate and multivariate analyses using a Cox proportional hazards model revealed that patients carrying the IL-2 −330G/G genotype had a significantly poorer prognosis than those carrying the T/G or T/T genotype. However, IL-2 −330T>G polymorphism was not associated with preoperative serum IL-2 levels. Moreover, interferon-γ, IL-12β, IL-4, and IL-10 genetic polymorphisms were not associated with prognosis after esophagectomy for thoracic esophageal squamous cell cancer.

Conclusions

It is suggested that IL-2 −330T>G genetic polymorphism may be a predictive factor for prognosis in patients receiving esophagectomy for thoracic esophageal squamous cell cancer.
Literature
1.
Kranzfelder M, Büchler P, Lange K, Friess H. Treatment options for squamous cell cancer of the esophagus: a systematic review of the literature. J Am Coll Surg. 2010;210:351–9.PubMedCrossRef
2.
3.
Mariette C, Taillier G, Van Seuningen I, Triboulet JP. Factors affecting postoperative course and survival after en bloc resection for esophageal carcinoma. Ann Thorac Surg. 2004;78:1177–83.PubMedCrossRef
4.
Stocker G, Ott K, Henningsen N, Becker K, Hapfelmeier A, Lordick F, et al. CyclinD1 and interleukin-1 receptor antagonist polymorphisms are associated with prognosis in neoadjuvant-treated gastric carcinoma. Eur J Cancer. 2009;45:3326–35.PubMedCrossRef
5.
Lurje G, Zhang W, Schultheis AM, Yang D, Groshen S, Hendifar AE, et al. Polymorphisms in VEGF and IL-8 predict tumor recurrence in stage III colon cancer. Ann Oncol. 2008;19:1734–41.PubMedCrossRef
6.
Schöndorf T, Eisele L, Göhring UJ, Valter MM, Warm M, Mallmann P, et al. The V109G polymorphism of the p27 gene CDKN1B indicates a worse outcome in node-negative breast cancer patients. Tumour Biol. 2004;25:306–12.PubMedCrossRef
7.
Liu G, Gurubhagavatula S, Zhou W, Wang Z, Yeap BY, Asomaning K, et al. Epidermal growth factor receptor polymorphisms and clinical outcomes in non-small-cell lung cancer patients treated with gefitinib. Pharmacogenomics J. 2008;8:129–38.PubMedCrossRef
8.
Lagmay JP, London WB, Gross TG, Termuhlen A, Sullivan N, Axel A, et al. Prognostic significance of interleukin-6 single nucleotide polymorphism genotypes in neuroblastoma: rs1800795 (promoter) and rs8192284 (receptor). Clin Cancer Res. 2009;15:5234–9.PubMedCrossRef
9.
Okuno T, Tamura T, Yamamori M, Chayahara N, Yamada T, Miki I, et al. Favorable genetic polymorphisms predictive of clinical outcome of chemoradiotherapy for stage II/III esophageal squamous cell carcinoma in Japanese. Am J Clin Oncol. 2007;30:252–7.PubMedCrossRef
10.
Sarbia M, Stahl M, von Weyhern C, Weirich G, Pühringer-Oppermann F. The prognostic significance of genetic polymorphisms (methylenetetrahydrofolate reductase C677T, methionine synthase A2756G, thymidilate synthase tandem repeat polymorphism) in multimodally treated oesophageal squamous cell carcinoma. Br J Cancer. 2006;94:203–7.PubMedCrossRef
11.
Wu X, Gu J, Wu TT, Swisher SG, Liao Z, Correa AM, et al. Genetic variations in radiation and chemotherapy drug action pathways predict clinical outcomes in esophageal cancer. J Clin Oncol. 2006;24:3789–98.PubMedCrossRef
12.
Yu H, Pardoll D, Jove R. STATs in cancer inflammation and immunity: a leading role for STAT3. Nat Rev Cancer. 2009;9:798–809.PubMedCrossRef
13.
Onoé K, Yanagawa Y, Minami K, Iijima N, Iwabuchi K. Th1 or Th2 balance regulated by interaction between dendritic cells and NKT cells. Immunol Res. 2007;38:319–32.PubMedCrossRef
14.
Ross OA, Curran MD, Meenagh A, Williams F, Barnett YA, Middleton D, et al. Study of age-association with cytokine gene polymorphisms in an aged Irish population. Mech Ageing Dev. 2003;124:199–206.PubMedCrossRef
15.
Pravica V, Perrey C, Stevens A, Lee JH, Hutchinson IV. A single nucleotide polymorphism in the first intron of the human IFN-gamma gene: absolute correlation with a polymorphic CA microsatellite marker of high IFN-gamma production. Hum Immunol. 2000;61:863–6.PubMedCrossRef
16.
Hall MA, McGlinn E, Coakley G, Fisher SA, Boki K, Middleton D, et al. Genetic polymorphism of IL-12 p40 gene in immune-mediated disease. Genes Immun. 2000;1:219–24.PubMedCrossRef
17.
Noguchi E, Shibasaki M, Arinami T, Takeda K, Yokouchi Y, Kawashima T, et al. Association of asthma and the interleukin-4 promoter gene in Japanese. Clin Exp Allergy. 1998;28:449–53.PubMedCrossRef
18.
Edwards-Smith CJ, Jonsson JR, Purdie DM, Bansal A, Shorthouse C, Powell EE. Interleukin-10 promoter polymorphism predicts initial response of chronic hepatitis C to interferon alfa. Hepatology. 1999;30:526–30.PubMedCrossRef
19.
Hyngstrom JR, Posner MC. Neoadjuvant strategies for the treatment of locally advanced esophageal cancer. J Surg Oncol. 2010;101:299–304.PubMedCrossRef
20.
Udagawa H. Chemoradiotherapy: its effectiveness, toxicity, and perspective in the treatment of esophageal cancer. Ann Thorac Cardiovasc Surg. 2009;15:359–61.PubMed
21.
Lucey DR, Clerici M, Shearer GM. Type 1 and type 2 cytokine dysregulation in human infectious, neoplastic, and inflammatory diseases. Clin Microbiol Rev. 1996;9:532–62.PubMed
22.
Sakaguchi S, Yamaguchi T, Nomura T, Ono M. Regulatory T cells and immune tolerance. Cell. 2008;133:775–87.PubMedCrossRef
23.
D’Souza WN, Lefrancois L. IL-2 is not required for the initiation of CD8 T cell cycling but sustains expansion. J Immunol. 2003;171:5727–35.PubMed
24.
Lenardo MJ. Interleukin-2 programs mouse alpha beta T lymphocytes for apoptosis. Nature. 1991;353:858–61.PubMedCrossRef
25.
John S, Turner D, Donn R, Sinnott P, Worthington J, Ollier WE, et al. Two novel biallelic polymorphisms in the IL-2 gene. Eur J Immunogenet. 1998;25:419–20.PubMedCrossRef
26.
Hoffmann SC, Stanley EM, Darrin Cox E, Craighead N, DiMercurio BS, Koziol DE, et al. Association of cytokine polymorphic inheritance and in vitro cytokine production in anti-CD3/CD28-stimulated peripheral blood lymphocytes. Transplantation. 2001;72:1444–50.PubMedCrossRef
27.
Matesanz F, Fedetz M, Leyva L, Delgado C, Fernandez O, Alcina A. Effects of the multiple sclerosis associated −330 promoter polymorphism in IL2 allelic expression. J Neuroimmunol. 2004;148:212–7.PubMedCrossRef
28.
Nishimura T, Nakui M, Sato M, Iwakabe K, Kitamura H, Sekimoto M, et al. The critical role of Th1-dominant immunity in tumor immunology. Cancer Chemother Pharmacol. 2000;46:52–61.CrossRef
Metadata
Title
Interleukin-2 −330T>G Genetic Polymorphism Associates with Prognosis Following Surgery for Thoracic Esophageal Squamous Cell Cancer
Authors
Satoru Motoyama, MD, PhD
Masatomo Miura, PhD
Yudai Hinai
Kiyotomi Maruyama, MD, PhD
Shuetsu Usami, MD, PhD
Kei Yoshino, MD
Toshinobu Nakatsu, MD
Hajime Saito, MD, PhD
Yoshihiro Minamiya, MD, PhD
Jun-ichi Ogawa, MD, PhD
Publication date
01-07-2011
Publisher
Springer-Verlag
Published in
Annals of Surgical Oncology / Issue 7/2011
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-011-1553-2

Other articles of this Issue 7/2011

Annals of Surgical Oncology 7/2011 Go to the issue

Colorectal Cancer

Association of C-reactive Protein Gene Polymorphisms and Colorectal Cancer

Melanomas

Does Increased Experience with Isolated Limb Infusion for Advanced Limb Melanoma Influence Outcome? A Comparison of Two Treatment Periods at a Single Institution

Translational Research and Biomarkers

Feasibility of ICG Fluorescence-Guided Sentinel Node Biopsy in animal Models using the HyperEye Medical System

Colorectal Cancer

OSNA-Based Novel Molecular Testing for Lymph Node Metastases in Colorectal Cancer Patients: Results from a Multicenter Clinical Performance Study in Japan

Breast Oncology

Poorer Survival Outcomes for Male Breast Cancer Compared with Female Breast Cancer May Be Attributable to In-Stage Migration

Gastrointestinal Oncology

Comparison of 6th and 7th AJCC TNM Staging Classification for Carcinoma of the Stomach in China